As Chinese biotech companies have faced a cash crunch at home, it has become necessary for them to look abroad for partnering opportunities to advance their assets through the clinic. This trend has led Johnson & Johnson to take an interest in linking arms with firms in China, albeit mindful of the current geopolitical climate, said Nauman Shah, global head of business development at Johnson & Johnson Innovation, at a 10 February fireside chat at the BIO CEO & Investor Conference.
Cash-Strapped Chinese Biotechs A Growing Draw For Western Pharma Partnering
Nauman Shah, head of business development for J&J Innovation, sat down at the BIO CEO & Investor Conference to talk about his trip to China and the state of the biotech scene there.
